Renal Cell Cancer Update

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Sara M Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data with antibody-drug conjugates in the management of breast cancer.CME information and select publications here.

Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists.CME information and select publications here.

Dr Stacey A Cohen from the University of Washington in Seattle, Dr Arvind Dasari from The University of Texas MD Anderson Cancer Center in Houston, and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora discuss the role of molecular residual disease assessment using circulating tumor DNA-based tools in the management of colorectal cancer.CME information and select publications here.

Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.CME information and select publications here.

Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.CME information and select publications here.

Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.CME information and select publications here.

Dr Ritu Salani from the David Geffen School of Medicine at UCLA in Los Angeles, California, reviews datasets from ESMO Congress 2025 relevant to the care of patients with gynecologic cancers.CME information and select publications here.

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

Dr Marwah Fakih from the City of Hope Comprehensive Cancer Center in Duarte, California, discusses current and potential therapeutic strategies for the treatment of squamous cell carcinoma of the anal canal.CME information and select publications here.

Dr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025.CME information and select publications here.

Dr Kathleen N Moore from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on available and novel treatment strategies with antibody-drug conjugates for ovarian cancer.CME information and select publications here.

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.CME information and select publications here.

Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.CME information and select publications here.

Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.

Dr Rana R McKay discusses the selection and sequencing of therapy for patients with prostate cancer in a review of recently presented clinical findings from ESMO Congress 2025.CME information and select publications here.

Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel KankeuFonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.CME information and select publications here.

Dr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer.CME information and select publications here.